Horiguchi A, Hatakeyama N, Ikeuchi K
Department of Urology, Otawara Red Cross Hospital.
Hinyokika Kiyo. 1999 Jan;45(1):31-5.
Prostate-specific antigen values provide important and unique information about prostate cancer to clinicians. However, there is conflicting information about the prognostic significance of the dynamics of PSA decline and elevation after treatment. To provide further insight into the dynamics of PSA as prognostic factors, we herein studied various PSA values as possible prognostic factors in 93 patients with prostate cancer treated with endocrine therapy. Thirteen (14.0%) had stage B tumors, 20 (21.5%) had stage C tumors, and 60 (64.5%) had stage D tumors. The overall 5-year survival rate was 41.2%. Relapse was observed in 32 (34.4%) patients. The influence of pre- and post-treatment PSA (both absolute and percentage values) on survival was analyzed. Normalization of PSA value was associated with prolonged survival regardless of interval to reach the lowest PSA level. The absolute value of PSA at 3 or 6 months following treatment was a significant discriminator, while the pre-treatment PSA level and percentage values of post-treatment PSA were not. These data show that the PSA nadir and PSA value at 3 or 6 months following treatment provide important prognostic information.
前列腺特异性抗原值为临床医生提供了有关前列腺癌的重要且独特的信息。然而，关于治疗后前列腺特异性抗原（PSA）下降和升高动态变化的预后意义，存在相互矛盾的信息。为了进一步深入了解PSA动态变化作为预后因素的情况，我们在此研究了93例接受内分泌治疗的前列腺癌患者中各种PSA值作为可能的预后因素。其中13例（14.0%）为B期肿瘤，20例（21.5%）为C期肿瘤，60例（64.5%）为D期肿瘤。总体5年生存率为41.2%。32例（34.4%）患者出现复发。分析了治疗前后PSA（绝对值和百分比值）对生存的影响。无论达到最低PSA水平的间隔时间如何，PSA值的正常化都与生存期延长相关。治疗后3个月或6个月时PSA的绝对值是一个重要的判别指标，而治疗前PSA水平和治疗后PSA的百分比值则不是。这些数据表明，PSA最低点以及治疗后3个月或6个月时的PSA值提供了重要的预后信息。
